Lung Cancer Stage III
Conditions
Keywords
Non small cell lung cancer, NSCLC, Stage III, Radiotherapy, Biomarker, Circulating-tumour DNA, Radiomics, PROM
Brief summary
In stage 3 NSCLC, treatment and follow-up are generally performed in a 'one-size-fits-all' manner. In the setting of metastatic lung cancer there has been considerable success identifying biomarkers, which allow treatments to be tailored and lead to more personalised medicine. In patients with stage 3 disease there exists a significant unmet clinical need for equivalent biomarkers to guide treatment decisions such as to identify poor responders, predict benefit from treatment and diagnose relapse before standard of care imaging. Recent advances have made it possible to detect and quantify circulating-tumour DNA in peripheral blood of patients with stage 3 NSCLC, a promising prognostic biomarker and a measure of minimal residual disease. In addition, the information contained in routine medical images and electronic patient reported outcome measure (ePROM) questionnaires can add further predictive power to circulating tumour DNA and other clinical factors to determine patient's outcome. There is scope to integrate biomarkers in treatment decision algorithms aiming to make personalised treatment modifications (e.g. decision to treat with immunotherapy or not). VIGILANCE is a highly exploratory observational study to understand how these biomarkers might inform a future hypothesis driven interventional study.
Interventions
None listed
Sponsors
Cancer Research UK
University of Manchester
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological or cytologically confirmed NSCLC. * Unsuitable for surgery due to tumour or patient factors. * Stage 3 A, B or C (TNM version 8). * Planned to receive radical radiotherapy OR sequential chemoradiotherapy OR concurrent chemoradiotherapy +/- consolidation immunotherapy. * Predicted life expectancy \>12 weeks. * Ability to provide written informed consent. * Willingness to comply with study procedures.
Exclusion criteria
* Mixed non-small cell and small cell tumours. * Adjuvant radiotherapy post-surgery. * Participation in a study of an interventional study as part of lung cancer treatment. * Recent/active malignant disease which might impact study results. * Psychotic disorders/cognitive impairment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prognostic model built using baseline and longitudinal circulating-tumour DNA, radiomic features and patient reported measures to predict survival, tumour control and early tumour relapse. | 2.5 years |
Secondary
| Measure | Time frame |
|---|---|
| Longitudinal description of circulating-tumour DNA patterns at baseline, during and for up to 1 year following completion of radiotherapy. | 2.5 years |
| Longitudinal description of radiomic features at baseline, during and for up to 1 year following completion of radiotherapy. | 2.5 years |
| Longitudinal description of patient reported outcomes at baseline, during and for up to 1 year following completion of radiotherapy. | 2.5 years |
| Predictive model built using baseline and longitudinal circulating-tumour DNA and radiomic features to predict benefit from consolidation immunotherapy. | 2.5 years |
| Associations between features and changes in features over time will be described, e.g. radiomic features associated with circulating-tumour DNA and radiomic features. | 2.5 years |
Countries
United Kingdom
Outcome results
None listed